The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

bit.bio is a synthetic biology company that uses its cell identity coding platform to reprogram induced pluripotent stem cells to create any human cell type. With its cell identity coding platform, ...

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...

Prof. Roger Pedersen, Stanford University, and Dr. Thomas Moreau, bit.bio, will give an overview of the innovative history and recent developments in transcription factor-mediated cellular ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

Research collaboration leverages bit.bio's machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European ...